Alembic Pharmaceuticals has reported results for third quarter ended December 31, 2018.
The company has reported a rise of 31.86% in its net profit at Rs 138.51 crore for the quarter under review as compared to Rs 105.04 crore for the same quarter in the previous year. Total income of the company increased by 20.24% at Rs 908.08 crore for Q3FY19 as compared Rs 755.23 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a rise of 30.04% in its net profit at Rs 169.83 crore for the quarter under review as compared to Rs 130.60 crore for the same quarter in the previous year. Total income of the company increased by 21.58% at Rs 1021.67 crore for Q3FY19 as compared Rs 840.34 crore for the corresponding quarter previous year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1538.60 |
Dr. Reddys Lab | 6101.60 |
Cipla | 1376.50 |
Zydus Lifesciences | 945.05 |
Lupin | 1625.65 |
View more.. |